Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc (CRNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Crinetics Pharmaceuticals Inc 6055 Lusk Boulevard San Diego CA 92121 USA

www.crinetics.com P: 858-450-6464

Description:

Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly, CRN02481 for the treatment of Hyperinsulinemias and CRN01941 for the treatment of Neuroendocrine Tumors which are in clinical stage. Crinetics Pharmaceuticals Inc is based in San Diego, United States.

Key Statistics

Overview:

Market Capitalization, $K 3,077,712
Enterprise Value, $K 3,022,812
Shares Outstanding, K 69,600
Annual Sales, $ 4,010 K
Annual Net Income, $ -214,530 K
Last Quarter Sales, $ 350 K
Last Quarter Net Income, $ -57,460 K
EBIT, $ -207,520 K
EBITDA, $ -212,690 K
60-Month Beta 0.63
% of Insider Shareholders 7.00%
% of Institutional Shareholders 98.51%
Float, K 64,728
% Float 93.00%
Short Volume Ratio 0.36

Growth:

1-Year Return 127.88%
3-Year Return 150.26%
5-Year Return 64.03%
5-Year Revenue Growth 65.02%
5-Year Earnings Growth -65.47%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.90 on 02/28/24
Latest Earnings Date 05/02/24
Earnings Per Share ttm -3.64
EPS Growth vs. Prev Qtr 10.89%
EPS Growth vs. Prev Year -7.14%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CRNX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -52.93%
Return-on-Assets % -45.54%
Profit Margin % -5,349.88%
Debt/Equity 0.00
Price/Sales 753.41
Price/Cash Flow N/A
Price/Book 5.32
Book Value/Share 10.02
Interest Coverage -2.60
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar